Immunotherapy in Melanoma | Specialty

Melanoma Excision Frequently Delayed in Medicare Population

April 8th 2015

One in five Medicare patients with melanoma waits more than 1.5 months after diagnosis to undergo surgery.

Abiraterone Label Expanded, Phase III Melanoma Data, SGR Repeal, and More

April 3rd 2015

Dr. Agarwala on the Role of Cytokines in the Immunotherapy Landscape

April 2nd 2015

Sanjiv S. Agarwala, MD, Chief of Medical Oncology, Hematology, St. Luke's Cancer Center and Temple University, discusses the differences between cytokines and other types of immunotherapies.

Dr. Joseph on Necessary Improvements on Immunotherapy in Melanoma

March 31st 2015

Richard W. Joseph, MD, Department of Hematology/Oncology, Mayo Clinic, discusses some improvements needed in the field of immunotherapy as a treatment for melanoma.

Frontline Pembrolizumab Bests Ipilimumab in Phase III Melanoma Trial

March 25th 2015

A trial comparing frontline pembrolizumab with ipilimumab for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints

Anti-PD-1 Therapy Poised to Take the Next Step in Melanoma

March 25th 2015

OncLive interviewed Jason J. Luke, MD, who discussed the clinical implications of immunotherapies in melanoma, with optimal sequencing and combinations emerging as the most pressing questions that researchers are seeking to answer in ongoing clinical trials.

Sam Donaldson on the Need for Optimistic Doctors

March 24th 2015

Former ABC News reporter Sam Donaldson, a melanoma survivor, describes the need for optimistic but realistic doctors.

Dr. Weber on Molecular Testing in Melanoma

March 23rd 2015

Jeffrey Weber, MD, PhD, a senior member at the Moffitt Cancer Center, discusses the significance of molecular testing for patients with melanoma and when testing should occur.

NRAS Mutations May Serve as Efficacy Biomarker for Immunotherapies in Melanoma

March 19th 2015

Patients with NRAS-mutated melanoma had better responses and improved treatment outcomes compared with those who did not harbor the mutation, according to a recent retrospective study.

Fresh Insight on Ipilimumab's Potential in the Adjuvant Melanoma Setting

March 17th 2015

In an interview with OncLive, Ahmad A. Tarhini, MD, PhD, discussed the benefits and challenges of ipilimumab and other immunotherapies and how they could change the adjuvant treatment paradigm for melanoma.

Dr. Luke on PD-1 Agents as Frontline Immunotherapy in Melanoma

March 13th 2015

Jason J. Luke, MD, FACP, assistant professor of medicine, Melanoma and Developmental Therapeutics Clinic, University of Chicago Medicine, discusses PD-1 inhibitors nivolumab and pembrolizumab as frontline immunotherapy choices for patients with melanoma.

Wistar-Penn Collaboration Identifies HSP70 as Promising New Target for Melanoma Therapy

March 12th 2015

A 10-year collaboration between scientists at The Wistar Institute and the University of Pennsylvania has recently resulted in the emergence of an exciting new target for cancer therapy, heat shock protein 70, that could be helpful in treating patients with melanoma.

Dr. Kim on Evolution of Treatment Outcomes in Melanoma

March 7th 2015

Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses how treatment outcomes in melanoma have evolved over the last few years.

FDA Accepts sBLA for Adjuvant Ipilimumab in Melanoma

March 2nd 2015

The FDA has accepted a supplemental Biologics License Application for ipilimumab for the adjuvant treatment of patients with stage III melanoma at high risk of recurrence following complete resection.

GSK, Novartis Product Exchange Completed

March 2nd 2015

GlaxoSmithKline (GSK) and Novartis have announced that a multi-billion-dollar, 3-pronged deal to exchange and share various operations has been completed.

FDA Approvals, Breakthrough Designations, Priority Reviews, and More

February 27th 2015

Five-Year Analysis Shows Ipilimumab More Than Doubles OS in Advanced Melanoma

February 27th 2015

In an analysis of phase III data, the 5-year survival rate with ipilimumab plus dacarbazine in patients with advanced melanoma was 18.2% versus 8.8% with dacarbazine alone.

PD-1 Inhibition Requires Further Refinement in Melanoma

February 25th 2015

In an interview with OncLive, Suzanne L. Topalian, MD, director of the Melanoma Program at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discussed the rapid advance of nivolumab and potential next-steps.

Closing Comments: Updates in Malignant Melanoma

February 24th 2015

Emerging Therapies for Malignant Melanoma

February 24th 2015